NAGOYA UNIVERSITY

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: Private

Established: 1871-01-01

Employees: 5K

Market Cap: -

Website: http://www.nagoya-u.ac.jp/en

Clinical Trials

Deep Learning-based Artificial Intelligence for the Diagnosis of Small Bowel Obstruction

Active, not recruiting

Conditions: Bowel Obstruction
Artificial Intelligence

Interventions: Diagnostic Test: Artificial intelligence

First Posted Date: 2024-07-01

Last Posted Date: 2024-07-01

Lead Sponsor: Nagoya University

Target Recruit Count: 17

Registration Number: NCT06481358

Locations: 🇯🇵
Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan

Investigator-initiated Clinical Trial of MIKE-1

Phase 1

Recruiting

Conditions: Pancreatic Cancer

Interventions: Drug: Am80
Drug: Gemcitabine
Drug: nab-Paclitaxel

First Posted Date: 2021-10-01

Last Posted Date: 2024-04-04

Lead Sponsor: Nagoya University

Target Recruit Count: 55

Registration Number: NCT05064618

Locations: 🇯🇵
Nagoya University Hospital, Nagoya, Aich, Japan
🇯🇵
The University of Tokyo Hospital, Tokyo, Japan

The Clinical Trial of ADR-001 for IgA Nephropathy

Phase 1

Completed

Conditions: Glomerulonephritis , IGA

Interventions: Biological: infusion of ADR-001 (Mesenchymal stem cell)

First Posted Date: 2020-04-13

Last Posted Date: 2023-05-01

Lead Sponsor: Nagoya University

Target Recruit Count: 9

Registration Number: NCT04342325

Locations: 🇯🇵
Kasugai Municipal Hospital, Kasugai, Aichi, Japan
🇯🇵
Nagoya University Hospital, Nagoya, Aichi, Japan

The Clinical Trial of CL2020 Cells for Neonatal Hypoxic Ischemic Encephalopathy

Phase 1

Completed

Conditions: Hypoxia-Ischemia, Brain

Interventions: Biological: CL2020 cells

First Posted Date: 2020-02-07

Last Posted Date: 2023-10-03

Lead Sponsor: Nagoya University

Target Recruit Count: 9

Registration Number: NCT04261335

Locations: 🇯🇵
Nagoya University Hospital, Nagoya, Aich, Japan

The Evaluation of Efficacy and Safety of Rituximab in Refractory CIDP Patients With IgG4 Autoantibodies

Phase 2

Completed

Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Interventions: Biological: Rituximab (genetical recombination)
Other: Placebo

First Posted Date: 2019-03-06

Last Posted Date: 2021-08-20

Lead Sponsor: Nagoya University

Target Recruit Count: 25

Registration Number: NCT03864185

Locations: 🇯🇵
Nagoya University Hospital, Nagoya, Aich, Japan
🇯🇵
Yamaguchi University Hospital, Ube, Japan
🇯🇵
Chiba University Hospital, Chiba, Japan

and more 1 locations

A Trial of the Irradiance Level of Phototherapy for Neonatal Jaundice

Not Applicable

Terminated

Conditions: Neonatal Jaundice

Interventions: Other: Low irradiance level of phototherapy
Other: High irradiance level of phototherapy

First Posted Date: 2017-02-16

Last Posted Date: 2023-10-03

Lead Sponsor: Nagoya University

Target Recruit Count: 100

Registration Number: NCT03055481

Locations: 🇯🇵
TOYOTA Memorial Hospital, Toyota, Aichi, Japan
🇯🇵
Handa City Hospital, Handa, Aichi, Japan
🇯🇵
Hekinan Municipal Hospital, Hekinan, Aichi, Japan

and more 5 locations

Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer

Phase 2

Conditions: Borderline Resectable Pancreatic Cancer

Interventions: Drug: FOLFIRINOX
Drug: gemcitabine + nab-paclitaxel

First Posted Date: 2016-03-23

Last Posted Date: 2020-09-10

Lead Sponsor: Nagoya University

Target Recruit Count: 50

Registration Number: NCT02717091

Clinical Trial of Autologous Adipose Derived Regenerative Cells for the Treatment of Male Stress Urinary Incontinence

Phase 3

Completed

Conditions: Urinary Incontinence , Stress

Interventions: Biological: Periurethral injection of autologous ADRCs and adipose tissue

First Posted Date: 2015-08-20

Last Posted Date: 2019-11-14

Lead Sponsor: Nagoya University

Target Recruit Count: 45

Registration Number: NCT02529865

Locations: 🇯🇵
Nagoya university Hospital, Nagoya, Aichi, Japan
🇯🇵
Kanazawa University Hospital, Kanazawa, Ishikawa, Japan
🇯🇵
Shinshu University Hospital, Matsumoto, Nagano, Japan

and more 1 locations

Eplerenone and Aliskiren Research Targeting Hypertensive Patients With Left Ventricular Hypertrophy

Phase 4

Conditions: Hypertensive Left Ventricular Hypertrophy

Interventions: Drug: Aliskiren
Drug: Eplerenone

First Posted Date: 2013-07-09

Last Posted Date: 2013-07-22

Lead Sponsor: Nagoya University

Target Recruit Count: 100

Registration Number: NCT01893788

Locations: 🇯🇵
Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan

Randomised Study Comparing Different Dosages of Rabbit ATG in Patients With SAA

Phase 3

Conditions: Acquired Aplastic Anemia.

Interventions: Drug: Thymoglobulin

First Posted Date: 2013-05-01

Last Posted Date: 2016-04-01

Lead Sponsor: Nagoya University

Target Recruit Count: 320

Registration Number: NCT01844635

Locations: 🇯🇵
Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy